Bulbine frutescens Phytochemicals as a Promising Anti-cancer Drug Discovery Source: A Computational Study

  • Prem P. Kushwaha
  • Ajay Kumar
  • Santosh Maurya
  • Atul K. Singh
  • Amit Kumar Sharma
  • Shashank Kumar


Deregulated signaling pathways/processes result in uncontrolled cell proliferation and cell survival. Adaptation to this condition often resulted in chemotherapeutic resistance in cancer cells. According to the concept of various signaling involvement in the development of cancer, fractional inhibition of numerous targets can be more productive than single one. Bulbine frutescens is a traditional medicinal plant of South Africa, has been preliminarily reported for anti-proliferative and anti-drug resistance property in cancer cells. Anticancer and mode of action of various phytochemicals present in the plant not yet has been studied. The present in silico study was designed to assess the potential B. frutescens phytochemicals as novel natural inhibitors of signaling proteins involved in cancer. Furthermore, drug-likeness property, ADME/T (absorption, distribution, metabolism, excretion/toxicity) properties, interaction ability with xenobiotic enzymes and biological activities were predicted by using various computational tools. For the first time Palmidin C, AC1NSTKE, Bulbine-knipholone and 4′-Demethylknipholone 2′-β-D-glucopyranoside compounds have been reported for their anticancer potential. These phytochemicals have better potential to inhibit NFkB, TGF-β, PI3K, and JAK2 proteins than their respective standard inhibitors. Lead phytochemicals showed better ADME/T, drug-likeness, xenobiotic enzymes interactions and biological activities. In conclusion, Palmidin C, AC1NSTKE and Bulbine-knipholone are the novel potent anticancer phytochemicals and need to be studied further in vitro and in vivo.


Cancer Signaling pathway Natural inhibitors Bulbine frutescens 



PPK and SK acknowledges financial support from UGC, India and Central University of Punjab Bathinda, Punjab, India for providing financial assistance in the form of UGC-CSIR Senior Research Fellowship and UGC-BSR Research Start-Up-Grant, [No.F.30-372/2017(BSR)] respectively.

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. Abdissa N, Heydenreich M, Midiwo JO, Ndakala A, Majer Z, Neumann B, Stammler HG, Sewald N, Yenesew A. A xanthone and a phenylanthraquinone from the roots of Bulbine frutescens, and the revision of six seco-anthraquinones into xanthones. Phytochem Lett. 2014;9:67–73.CrossRefGoogle Scholar
  2. Abegaz BM, Bezabih M, Msuta T, Brun R, Menche D, Muhlbacher J, Bringmann G. Gaboroquinones A and B and 4′-O-demethylknipholone-4′-O-beta-D-glucopyranoside, phenylanthraquinones from the roots of Bulbine frutescens. J Nat Prod. 2002;65:1117–21.CrossRefGoogle Scholar
  3. Berman H, Henrick K, Nakamura H, Markley JL. The worldwide Protein Data Bank (wwpdb): ensuring a single, uniform archive of PDB data. Nucleic Acids Res. 2006;35:301–3.CrossRefGoogle Scholar
  4. Bolton EE, Wang Y, Thiessen PA, Bryant SH. PubChem integrated platform of small molecules and biological activities. Annu Rep Comput Chem. 2008;4:217–41.CrossRefGoogle Scholar
  5. Bringmann G, Mutanyatta-Comar J, Maksimenka K, Wanjohi JM, Heydenreich M, Brun R, Müller WE, Peter MG, Midiwo JO, Yenesew A. Joziknipholones A and B: the first dimeric phenylanthraquinones, from the roots of Bulbine frutescens. Chemical. 2008;14:1420–9.CrossRefGoogle Scholar
  6. Chen X, Du Y, Nan J, Zhang X, Qin X, Wang Y, Hou J, Wang Q, Yang J. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One. 2013;8:e63697.CrossRefGoogle Scholar
  7. Dallakyan S. PyRx-python prescription v. 0.8. La Jolla: The Scripps Research Institute; 2010.Google Scholar
  8. Duvoix A, Morceau F, Delhalle S, Schmitz M, Schnekenburger M, Galteau MM, Dicato M, Diederich M. Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochem Pharmacol. 2003;66:1475–83.CrossRefGoogle Scholar
  9. Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005;7:509–21.CrossRefGoogle Scholar
  10. Kaliberov SA, Buchsbaum DJ. Cancer treatment with gene therapy and radiation therapy. Adv Cancer Res. 2012;115:221–63.CrossRefGoogle Scholar
  11. Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Dis Dev. 2009;12:189–96.Google Scholar
  12. Laskowski RA, Swindells MB. LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51:2778–86.CrossRefGoogle Scholar
  13. Lee SK, Lee IH, Kim HJ, Chang GS, Chung JE, No KT. The PreADME approach: web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties. EuroQSAR 2002 Designing Drugs and Crop Protectants: processes, problems and solutions. 2003. p. 418–20.Google Scholar
  14. Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, Lee HJ, Surh YJ, Bowden GT, Dong Z. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis. 2007;28:1918–27.CrossRefGoogle Scholar
  15. Lu L, Li K, Mao YH, Qu H, Yao B, Zhong WW, Ma B, Wang ZY. Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo. Int J Oncol. 2017;51:1089–103.CrossRefGoogle Scholar
  16. Matsui WH. Cancer stem cell signaling pathways. Medicine (Baltimore). 2016;95:S8–S19.CrossRefGoogle Scholar
  17. Mouli KC, Vijaya T, Rao SD. Phytoresources as potential therapeutic agents for cancer treatment and prevention. J Global Pharma Tech. 2009;1:4–18.Google Scholar
  18. Mukanganyama S, Bezabih M, Robert M, Ngadjui BT, Kapche GF, Ngandeu F, Abegaz B. The evaluation of novel natural products as inhibitors of human glutathione transferase P1-1. J Enzyme Inhib Med Chem. 2011;26:460–7.CrossRefGoogle Scholar
  19. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open babel: an open chemical toolbox. J Cheminform. 2011;3:33.CrossRefGoogle Scholar
  20. Pather N, Kramer B. Bulbine natalensis and Bulbine frutescens promote cutaneous wound healing. J Ethnopharmacol. 2012;144:523–32.CrossRefGoogle Scholar
  21. Pather N, Viljoen AM, Kramer B. A biochemical comparison of the in vivo effects of Bulbine frutescens and Bulbine natalensis on cutaneous wound healing. J Ethnopharmacol. 2011;133:364–70.CrossRefGoogle Scholar
  22. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera- a visualization system for exploratory research and analysis. J Comput Chem. 2004;13:1605–12.CrossRefGoogle Scholar
  23. Pinar R. To investigate knowledge of Turkish people about cancer. Cancer Agenda. 1998;12:66–73.Google Scholar
  24. Tambama P, Abegaz B, Mukanganyama S. Antiproliferative activity of the isofuranonaphthoquinone isolated from Bulbine frutescens against jurkat T cells. Biomed Res Int. 2014;2014:1–14.CrossRefGoogle Scholar
  25. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–61.PubMedPubMedCentralGoogle Scholar
  26. van Huyssteen M, Milne PJ, Campbell EE, van de Venter M. Antidiabetic and cytotoxicity screening of five medicinal plants used by traditional African health practitioners in the Nelson Mandela Metropole, South Africa. Afr J Tradit Complement Altern Med. 2011;8:150–08.PubMedGoogle Scholar
  27. van Staden LF, Drewes SE. Knipholone from Bulbine latifolia and Bulbine frutescens. Phytochemistry. 1994;35:685–6.CrossRefGoogle Scholar
  28. Widgerow AD, Chait LA, Stals R, Stals PJ. New innovations in scar management. Aesthet Plast Surg. 2000;24:227–34.CrossRefGoogle Scholar
  29. Wu T, Chen C, Li F, Chen Z, Xu Y, Xiao B, Tao Z. 3,3′-Diindolylmethane inhibits the invasion and metastasis of nasopharyngeal carcinoma cells in vitro and in vivo by regulation of epithelial mesenchymal transition. Exp Ther Med. 2014;7:1635–8.CrossRefGoogle Scholar
  30. Xu C, Li CYT, Kong ANT. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005;28:249.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Prem P. Kushwaha
    • 1
  • Ajay Kumar
    • 1
  • Santosh Maurya
    • 1
  • Atul K. Singh
    • 1
  • Amit Kumar Sharma
    • 2
  • Shashank Kumar
    • 1
  1. 1.Department of Biochemistry and Microbial SciencesCentral University of PunjabBathindaIndia
  2. 2.Department of AgricultureUttaranchal UniversityDehradunIndia

Personalised recommendations